Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
Ito A, Horie I, Miwa M, Sako A, Niri T, Nakashima Y, Shigeno R, Haraguchi A, Natsuda S, Akazawa S, Kamada A, Kawakami A, Abiru N. Ito A, et al. J Diabetes Investig. 2021 Aug;12(8):1367-1376. doi: 10.1111/jdi.13486. Epub 2021 Jan 22. J Diabetes Investig. 2021. PMID: 33369175 Free PMC article.
Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
Horie I, Haraguchi A, Sako A, Akeshima J, Niri T, Shigeno R, Ito A, Nozaki A, Natsuda S, Akazawa S, Mori Y, Ando T, Kawakami A, Abiru N. Horie I, et al. Among authors: ito a. Diabetes Res Clin Pract. 2018 Oct;144:161-170. doi: 10.1016/j.diabres.2018.08.015. Epub 2018 Sep 6. Diabetes Res Clin Pract. 2018. PMID: 30194951 Clinical Trial.
Impaired early-phase suppression of glucagon secretion after glucose load is associated with insulin requirement during pregnancy in gestational diabetes.
Horie I, Haraguchi A, Ito A, Nozaki A, Natsuda S, Akazawa S, Mori Y, Ando T, Higashijima A, Hasegawa Y, Yoshida A, Miura K, Masuzaki H, Kawakami A, Abiru N. Horie I, et al. Among authors: ito a. J Diabetes Investig. 2020 Jan;11(1):232-240. doi: 10.1111/jdi.13096. Epub 2019 Jul 2. J Diabetes Investig. 2020. PMID: 31179612 Free PMC article. Clinical Trial.
Bihormonal dysregulation of insulin and glucagon contributes to glucose intolerance development at one year post-delivery in women with gestational diabetes: a prospective cohort study using an early postpartum 75-g glucose tolerance test.
Shigeno R, Horie I, Miwa M, Ito A, Haraguchi A, Natsuda S, Akazawa S, Nagata A, Hasegawa Y, Miura S, Miura K, Kawakami A, Abiru N. Shigeno R, et al. Among authors: ito a. Endocr J. 2021 Aug 28;68(8):919-931. doi: 10.1507/endocrj.EJ20-0795. Epub 2021 Apr 6. Endocr J. 2021. PMID: 33827994 Free article.
The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A, Shigeno R, Horie I, Morimoto S, Ito A, Chiba K, Kawazoe Y, Tashiro S, Miyamoto J, Sato S, Yamamoto H, Osaki M, Kawakami A, Abiru N. Haraguchi A, et al. Among authors: ito a. Trials. 2020 May 5;21(1):379. doi: 10.1186/s13063-020-04276-4. Trials. 2020. PMID: 32370806 Free PMC article.
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
Nakamura Y, Haraguchi A, Shigeno R, Ito A, Horie I, Kawakami A, Abiru N. Nakamura Y, et al. Among authors: ito a. Medicine (Baltimore). 2021 Mar 12;100(10):e25100. doi: 10.1097/MD.0000000000025100. Medicine (Baltimore). 2021. PMID: 33725905 Free PMC article.
RENAL FUNCTION AND PLASMA RENIN ACTIVITY AS POTENTIAL FACTORS CAUSING HYPERKALEMIA IN PATIENTS WITH THYROID CARCINOMA UNDERGOING THYROID HORMONE WITHDRAWAL FOR RADIOACTIVE IODINE THERAPY.
Niri T, Horie I, Ando T, Kawahara H, Ueda M, Eto M, Sako A, Ikeuchi Y, Nakao T, Nakashima Y, Shigeno R, Ito A, Nozaki A, Haraguchi A, Natsuda S, Sagara I, Akazawa S, Kamada A, Imaizumi M, Abiru N, Usa T, Kawakami A. Niri T, et al. Among authors: ito a. Endocr Pract. 2020 Feb;26(2):197-206. doi: 10.4158/EP-2019-0374. Epub 2019 Oct 25. Endocr Pract. 2020. PMID: 31652100
4,427 results